The more gasoline rises above $5, the greater risk there is of recession
Gasoline is nearing an average $5 per gallon across the U.S., but prices would have to go higher and stay elevated to cause a recession, economists say.
Stitch Fix is laying off 15% of its salaried employees, internal memo says
Stitch Fix is laying off 15% of salaried positions within its workforce, mostly in corporate roles and styling leadership positions.
The ‘dividend aristocrats’ are beating the market this year. Here’s how investors can take advantage
Stocks that consistently grow their dividends have beaten the S&P 500 in 2022, and this ProShares ETF tracks those names.
Stocks making the biggest moves midday: Tesla, Five Below, Novavax, Nio and more
These are the stocks posting the largest moves in midday trading.
Santoli: The market is indecisive in advance of the next big catalyst, Friday’s inflation report
This is the daily notebook of Mike Santoli, CNBC’s senior markets commentator, with ideas about trends, stocks and market statistics.
Alibaba shares drop 8% after Jack Ma’s Ant Group and regulator squash talk of revived IPO
Ant Group, which is controlled by billionaire Alibaba founder Jack Ma, had its IPO pulled in November 2020 after regulators flagged concerns.
Sanders, Warren bill would extend Social Security solvency for 75 years, up benefits $2,400 a year
A new Democratic plan calls for repairing Social Security’s trust funds by raising taxes on the wealthy, while also making benefits more generous.
This SPAC is merging with an already-public company as sponsors get creative before time runs out
Many sponsors face challenges as they race the clock to find a target amid regulatory crackdown and waning enthusiasm.
Why remaining private is a competitive advantage for PE firm Bain Capital with $160 billion
John Connaughton, Bain Capital’s global head of Private Equity, talked about headwinds facing the industry and why his firm is staying private.
Signs point to biotech M&A heating up, Wells Fargo says. Here’s where to look
“Big BioPharma needs growth,” says Wells Fargo analyst Mohit Bansal in a research note that anticipates a pick-up in smaller deals in the sector.